Sah Dinah Ph.D. 4

Accession 0001104659-18-014162

CIK 0001640266other

View on SEC.gov Company Profile

Filed

Feb 28, 7:00 PM ET

Accepted

Mar 1, 6:00 PM ET

Size

21.0 KB

Accession

0001104659-18-014162

Insider Transaction Report

Form 4

Period: 2018-02-27

Voyager Therapeutics, Inc.VYGR

Sah Dinah Ph.D.

Chief Scientific Officer

Transactions

Exercise/Conversion
Common Stock
2018-02-27$7.27/sh−2,184$15,878→ 140,872 total
Sale
Common Stock
2018-02-27$30.00/sh−15,623$468,690→ 138,688 total
Exercise/Conversion
Common Stock
2018-02-27$11.09/sh−5,000$55,450→ 150,248 total
Exercise/Conversion
Stock Option (Right to Buy)
2018-02-27−5,000→ 35,000 total
Exercise: $11.09Exp: 2026-02-01→ Common Stock (5,000 underlying)
Exercise/Conversion
Common Stock
2018-02-27$11.83/sh−4,063$48,065→ 154,311 total
Exercise/Conversion
Stock Option (Right to Buy)
2018-02-27−4,376→ 28,570 total
Exercise: $8.33Exp: 2025-08-25→ Common Stock (4,376 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2018-02-27−2,184→ 12,957 total
Exercise: $7.27Exp: 2025-04-25→ Common Stock (2,184 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2018-02-27−4,063→ 60,937 total
Exercise: $11.83Exp: 2027-02-08→ Common Stock (4,063 underlying)
Exercise/Conversion
Common Stock
2018-02-27$8.33/sh−4,376$36,452→ 145,248 total

Footnotes (5)

[F1]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
[F2]The reporting person's Form 3, filed on July 7, 2017, erroneously reported the vesting schedule of this option. This option is scheduled to vest over four years in equal monthly installments, with 1/48th of the shares underlying such option vesting on the one-month anniversary of January 1, 2015, and 1/48th of the shares underlying such option vesting monthly thereafter.
[F3]The reporting person's Form 3, filed on July 7, 2017, erroneously reported the vesting schedule of this option. This option is scheduled to vest over four years in equal monthly installments, with 1/48th of the shares underlying such option vesting on the one-month anniversary of August 1, 2015, and 1/48th of the shares underlying such option vesting monthly thereafter. This Form 4 also aggregates identical options which were reported separately on the reporting person's Form 3.
[F4]The reporting person's Form 3, filed on July 7, 2017, erroneously reported the vesting schedule of this option. This option is scheduled to vest over four years in equal monthly installments, with 1/48th of the shares underlying such option vesting on the one-month anniversary of February 1, 2016, and 1/48th of the shares underlying such option vesting monthly thereafter. This Form 4 also aggregates identical options which were reported separately on the reporting person's Form 3.
[F5]The reporting person's Form 3, filed on July 7, 2017, erroneously reported the vesting schedule of this option. This option is scheduled to vest over four years in equal monthly installments, with 1/48th of the shares underlying such option vesting on the one-month anniversary of February 8, 2017, and 1/48th of the shares underlying such option vesting monthly thereafter. This Form 4 also aggregates identical options which were reported separately on the reporting person's Form 3.

Documents

1 file

4
a4.xmlPrimary
4

Issuer

Voyager Therapeutics, Inc.

CIK 0001640266

→

Entity typeother

Related Parties

filerCIK 0001711043

Filing Metadata

Form type: 4
Filed: Feb 28, 7:00 PM ET
Accepted: Mar 1, 6:00 PM ET
Size: 21.0 KB

View on SEC.gov